Rheumatoid Arthritis

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Patients with rheumatoid arthritis taking at least 3 targeted therapies were found to have a greater risk of developing herpes zoster.

Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

Olumiant shows favorable long-term safety profile in rheumatoid arthritis.

Study evaluates the safety profile of upadacitinib at 15 mg and 30 mg once daily for patients with moderately to severely active rheumatoid arthritis.

Agency gives green light to supplemental new drug application for repository corticotropin injection.

Xeljanz can be used for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.

AbbVie announced positive top-line results from a phase 3 trial for the efficacy and safety of upadacitinib for individuals with the rheumatic disease.

Oral use of glucosamine hydrochloride may reduce pain related to rheumatoid arthritis.

Ten quiz questions to assess your knowledge on common rheumatoid arthritis treatments.

A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.

After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.

The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.

A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.

Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.

The Mediterranean diet has shown efficacy in preventing several noncommunicable diseases.

The new studies found that for some patients, the use of steroid medications to reduce inflammation slighly increased the likelihood of needing hospital care for COVID-19.

Extended glucocorticoid use can cause complications such as cardiovascular disorders, infections, and osteoporosis, according to a new study.

What characteristics of RA treatments possibly connect to COVID-19 treatment?

The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).

It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) agreed on a positive opinion for AbbVie’s upadacitinib (RINVOQ), according to the company.

Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.